High-dose erythropoietin therapy for the purpose of brain protection in neonatal hypoxic-ischemic encephalopathy

High-dose erythropoietin therapy for the purpose of brain protection in neonatal hypoxic-ischemic encephalopathy - High-dose erythropoietin therapy for neonatal hypoxic-ischemic encephalopathy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012689

Enrollment

Registered

2013-12-25

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic-ischemic encephalopathy

Interventions

Five days injection of erythropoietin (2500 units / kg) in neonates with severe asphyxia.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The neonatal cases of severe asphyxia. Apgar score at 5min 3> umbilical cord blood,arterial-venous blood ph 7>, Sarnat classification stage III, aEEG higher voltage <5 microV

Exclusion criteria

Exclusion criteria: Congenital malformations, chromosomal abnormalities

Design outcomes

Primary

Measure	Time frame
EEG, brain ultrasonography:neonatal period: brain MRI:within 1 month,1year blood exam(Hb,plt):day1,3,7,14,30 18 month:developmental test	—

Countries

Japan

Contacts

Public ContactMasashi Hasegawa

Osaka Medical College Hospital Pediatrics

ped082@poh.osaka-med.ac.jp0726831221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026